

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

L 987587 476US

September 15, 2003

Date of Deposit

CASE 4-20437D

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

GURNY ET AL.

APPLICATION NO: 10/623,888

FILED: JULY 17, 2003

FOR: NANOPARTICLES FOR ORAL ADMINISTRATION OF PHARMACEUTICAL

AGENTS OF LOW SOLUBILITY

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants wish to make of record the references cited on attached forms PTO-1449 (5 sheets) and PTO-892 (3 sheets), which are copied from parent applications 08/945,587, November 20, 1997, abandoned, 09/287,421, April 7, 1999, abandoned, and 09/458,622, December 10, 1999, abandoned. Copies of the references are not enclosed.

Applicants also wish to make of record application 09/407,816, a copy of which was provided in parent application 09/458,622. Application '816 has now issued as U.S. Patent 6,503,883, a copy of which is enclosed.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO forms.

Respectfully submitted,

Novartis Corporate Intellectual Property One Health Plaza, Building 430 East Hanover, NJ 07936-1080

encl PTO forms (8 sheets) + 1 patent

Date: September 15, 2003

Gabriel Lopez

Attorney for Applicants

Reg. No. 28,440 (862) 778-7882

FORM PTO-1449 (REV. 7-85)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION ral sheets if necessary) 1 5 2003

ATTY. DOCKET NO. 4-20437/A/PCT/CONT APPLICATION NO. Not Yet Known **APPLICANT GURNY ET AL.** FILING DATE Herewith

Group 1643

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	5,382,435	1/17/95	Geary et al.	424	489	
	AB	5,206;219 🗸	4/1/93	Desai	514	003	
	AC	5,286,731 🗸	2/1/94	Caufield et al.	514	291	
	AD	5,342,625 🗸	8/1/94	Hauer et al.	424	456	
	AE	5,541,171	7/1/96	Rhodes et al.	514	166	
	AF	3,959,540 √	5/25/76	Leiberich et al.	428	35	
	AG	5,401,512	3/28/95	Rhodes et al.	424	458	
	АН	5,133,908	7/28/92	Stainmesse et al.	264	4.1	
	Al	<u> </u>					
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRAN YES	SLATION NO
	AM	0275796	7/27/88	European Patent Office	•			
-	AN	2166651 *	5/14/86	Great Britain				
	AO	B-10851/83 J	8/11/83	Australia -				
	AP	0225189 🗸	6/1/87	Europe				
	AQ	0148811	7/1/85	Europe				

HER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AR	R. Bodmeier et al., "Spontaneous Formation of Drug-containing Acrylic Nanoparti Microencapsulation, Vol. 8, No. 2, 1991, pp. 161-170	icies, ocumaror
AS	E. Allemann et al., "Drug-Loaded Nanoparticles - Preparation Methods and Drug European Journal of Pharmaceutics and Biopharmaceutics, Vol. 39, No. 5, 1993,	
AT	Handbook of Pharmaceutical Excipients, pp. 362-365	./

EXAMINER

DATE CONSIDERED

Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449 (REV. 7-85) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

Oseseveral sheets if necessary)

ATTY. DOCKET NO.
4-20437/A/PCT/CONT
APPLICATION NO.
Not Yet Known
APPLICANT
GURNY ET AL.
FILING DATE
Herewith

Group 1643

FOREIGN PATENT DOCUMENTS

	DOCUMENT	DATE	OFFICE	CLASS	SUBCLASS	TRAN	SLATION NO
^^		2/1/02	Europo		<u> </u>		
	 					<u> </u>	
	229065A	1/17/96	Great Britain				
			<u> </u>				
AE							
AF							
AG					,		
AH			·				
ΑI							
AJ							
AK							
AL							
AM	,						
AN							
AO	·						
AP							
AQ							
AR					<u> </u>		
AS					 		
AT							
AU			 				
AV			 				
							1
		 				 	1=
			 			 	
AZ							十一
	AG AH AI AJ AK AL AM AN AO AP AQ AR AS AT AU AV AW AX AY	AA 0533433 / AB 229065A AC AD AE AF AG AH AI AI AI AN AN AN AO AP AQ AR AS AT AU AV AW AX AY	NUMBER AA 0533433 3/1/93 AB 229065A 1/17/96 AC AC AC AD AC AC AE AC AC AF AC AC AH AC AC AK AC AC AN AC AC AP AC AC AR AC AC AT AC AC AW AC AC AW AC AC AW AC AC AW AC AC AX AC AC AX<	NUMBER Surope AA 0533433 3/1/93 Europe AB 229065A 1/17/96 Great Britain AC AD AB AB AE AB AB AB AF AB AB AB AH AB AB AB AI AB AB AB AN AB AB AB AP AB AB AB AT AB AB AB AV AB AB AB AY AB AB AB AB AB A	NUMBER AA 0533433 3/1/93 Europe AB 229065A 1/17/96 Great Britain AC AD AD AE AB AD AF AB AD AG AB AD AH AB AD AK AB AB AN AD AD AP AD AD AP AD AD AR AB AD AT AU AD AV AD AD AV AD AD AX AY AD	NUMBER Surope AA 0533433 3/1/93 Europe AB 229065A 1/17/96 Great Britain AC AB AB AB AE AB AB AB AF AB AB AB AH AB AB AB AJ AB AB AB AK AB AB AB AN AB AB AB AQ AB AB AB AR AB AB AB AT AB AB AB AV AB AB AB AV AB AB AB AV AB AB AB AV AB AB AB AB AB AB AB AB AB AB AB AB AB AB AB AB AB A	AA 0533433 / 3/1/93 Europe

EXAMINER

DATE CONSIDERED

^{*}EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449 (REVy 7-85)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

everal sheets if necessary) SEP 1 5 2003

ATTY. DOCKET NO. 4-20437/A/PCT/CONT APPLICATION NO. Not Yet Known APPLICANT GURNY ET AL. FILING DATE Herewith

Group 1643

E		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)
Name of the second	AA	Derwent Abstracts 90-056185, "Spergualin Preparation Containing Lipids"
	AB	Derwent Abstracts 89/301642/42 "Pharmaceutical compsn. for treating stomach disorders, etc comprises active components dispersed with silicon oil mixt. and encapsulated in soft gelatin"
-	AC	Derwent Abstract 90-083371/11 "Enteric solid dosage forms - contg. active peptide or protein and nonionic surfactant"
	ΑD	Derwent Abstracts 95-355166/46 "Adjuvants for Improved Oral Absorption"
	AE	
	AF	
	AG	
	АН	
	Al	
	AJ	
	AK	`
	AL	
	AM	
	AN	
EXAMINE	₹	DATE CONSIDERED

^{*}EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

Sheet 1 of 1

FORM PTO-1449 (REV. 7-85) U.S. DEP MENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

SEP 1 5 2003 N

ATTY. DET NO. 4-20437C APPLICATION NO. 09/458,622 APPLICANT GURNY ET AL. FILING DATE DECEMBER 10, 1999

Group 1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	L	DOCUMENT NUMBER	DATE	NAME	CU	ASS SUBCLA	ss	FILING DATE
	AA	5,350,741	9/27/94	Takada				
	АВ	5,624,687	4/29/97	Yano et al.				
	AC							
	AD	,						
	AE							
	AF							
	AG							
	АН							
	Al							
	AJ							
	AK							
	AL							
			FOREIG	N PATENT DOCUMENTS				
		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRA YES	NSLATION NO
	AM	343,575	8/26/92	EP (+ Abstract)				
	AN							
								ĪĒ
	AO			J	_1		ᆝᆜ	
	AO AP				 			一
								
	AP	OTHER DOC	UMENTS (Including Author, Title, Date, Pertin	ent pages, E	tc.)		
	AP AQ	OTHER DOC	UMENTS (Including Author, Title, Date, Pertin	ent pages, E	tc.)		
	AP	OTHER DOC	UMENTS (Including Author, Title, Date, Pertin	ent pages, E	tc.)		
	AP AQ	OTHER DOC	UMENTS (Including Author, Title, Date, Pertin	ent pages, E	tc.)		
	AP AQ AR	OTHER DOC	UMENTS (Including Author, Title, Date, Pertin	ent pages, E	tc.)		

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.